The cAd3 ebola vaccine, developed by Glaxo Smith Kline and the US National Institute of Health and imported by the CBF, was recently labelled and shipped for a Phase Ib vaccine trial taking place in Mali. The trial is run by the University of Maryland in conjunction with the Malian Ministry of Health and 40 volunteers will be vaccinated to further test the safety and immunogenicity of the adenovirus vaccine.

See this report from the BBC News about the trial and the University news for an overview of ebola research activities at the University of Oxford.

Mali label